In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more.

• Intro :37
• Welcome to another episode of Eye Care insider :51
• About Arthur Benjamin, MD 1:02
• I wonder if you could talk about your training and what you currently do now? 1:39
• Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56
• What is your current algorithm for someone with dry eye? How do you manage that? 5:01
• Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00
• With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54
• I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54
• What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07
• What a fascinating discussion 17:43
• Any last words? 17:55
• Outro 18:09

Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.  

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.